Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study

Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study

Background: The chronic myeloid leukaemia population, treatment patterns and responses in Portugal are unknown. The aim of this study is to describe these features in a Portuguese reference centre. Methods: A retrospective cohort study included patients with chronic myeloid leukaemia, treated betwee...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ana Maria Meireles, Rita Calisto, Maria José Bento, Pedro Martinho Gouveia, Susana Bizarro, Manuel Teixeira, Cláudia Moreira, Ana Espírito Santo, Mário Mariz
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Series:	Hematology, Transfusion and Cell Therapy
Subjects:	Chronic myelogenous leukaemia BCR-ABL positive Imatinib mesylate Tyrosine kinase inhibitors Epidemiology Myeloproliferative disorders
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137925002032
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
by: Pratik Deb, et al.
Published: (2014-01-01)

Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions
by: Irena Philipova, et al.
Published: (2025-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?
by: Cristina Madaudo, et al.
Published: (2025-04-01)

Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase
by: Sekulić Borivoj, et al.
Published: (2022-01-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia
by: Begoña San José Ruiz, et al.
Published: (2015-01-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia
by: Denčić-Fekete Marija, et al.
Published: (2021-01-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)

Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study
by: Alaa Fadhil Alwan, et al.
Published: (2025-01-01)

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells
by: Masanobu Tsubaki, et al.
Published: (2025-01-01)

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
by: Zhen-Yu Xiong, et al.
Published: (2024-12-01)

Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients
by: Phu Chi Dung, et al.
Published: (2025-01-01)

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
by: Rima Hajjo, et al.
Published: (2025-06-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: K. Kotlyarchuk, et al.
Published: (2015-09-01)

Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis
by: I. N. Mikhaylova, et al.
Published: (2021-01-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

Evolution of therapeutic approaches in patients with chronic myeloid leukemia and T315I mutation
by: A. G. Turkina, et al.
Published: (2024-12-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019-05-01)

Determination of imatinib mesylate and erlotinib hydrochloride in mice plasma using ultrahigh performance liquid chromatography method
by: Gülen Melike Demir, et al.
Published: (2018-08-01)

Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
by: Eun Hyea Park, et al.
Published: (2018-12-01)

Dermatofibrosarcoma: report of a case with complete response to imatinib and conservative surgery during the COVID-19 pandemic
by: Rafael Martins Steffen, et al.
Published: (2022-10-01)

PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells
by: ES Kolotova, et al.
Published: (2016-01-01)

Cytogenetic landscape aberrations in paediatric acute lymphoblastic leukaemia — a polish paediatric population treated according to ALL-IC BFM 2009 protocol
by: Monika Lejman, et al.
Published: (2025-07-01)

Using the Minor Variant Finder software to identify and quantify the allelic burden level of somatic mutations in oncohematologic diseases
by: T. N. Subbotina, et al.
Published: (2020-07-01)

Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients
by: Maedeh Khosravi, et al.
Published: (2021-05-01)

Evaluating the correlation of Age and Gender with the Hematological Parameters of the Chronic Myeloid Leukemia Patients
by: Farooq I. Mohammad, et al.
Published: (2025-04-01)

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience
by: Jwa Hoon Kim, et al.
Published: (2019-03-01)

From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents
by: Sarah K. Tasian, et al.
Published: (2025-12-01)

Demographic and clinical characteristics of chronic myeloid leukemia patients: A study on confined populations of Southern India
by: Manjula Gorre, et al.
Published: (2019-01-01)

Current and future of targeted therapies against BCR::ABL kinases
by: Sridhar Jayavel, et al.
Published: (2025-04-01)

Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature
by: Ekaterina Chelysheva, et al.
Published: (2018-05-01)

Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report
by: Sara Di Giusto, et al.
Published: (2025-08-01)

Chronic myeloid leukemia in childhood: a case report
by: Uma Bhatta, et al.
Published: (2021-09-01)

3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib
by: David Cabezas, et al.
Published: (2025-06-01)